Cullinan Oncology

$13.68 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Cullinan Oncology

Cullinan Oncology, Inc., formerly Cullinan Management, Inc. is a biopharmaceutical company. The Company is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. The Company’s lead candidate, CLN-081, is an orally available small molecule designed as an irreversible epidermal growth factor receptor (EGFR), inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion (EGFRex20ins), mutations, with relative sparing of cells expressing wild type EGFR. The Company’s evaluating CLN-081 as a treatment for non-small cell lung cancer (NSCLC), in adult patients with EGFRex20ins mutations in a Phase I/IIa trial. The Company’s other product candidates include CLN-049, CLN-619, CLN-617, CLN-978, Opal and Jade.

Stock Analysis

last close $13.68
1-mo return -0.1%
3-mo return 52%
avg daily vol. 186.3T
52-week high 30.33
52-week low 7.3
market cap. $624M
forward pe 4.2
annual div. -
roe -17.5%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 83.6%
baraka

Subscribe now for daily local and international financial news

Subscribe